{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:05:20Z","timestamp":1791273920410,"version":"4.1.0"},"reference-count":218,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,4,1]],"date-time":"1999-04-01T00:00:00Z","timestamp":922924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[1999,4]]},"DOI":"10.4065\/74.4.420","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:16:10Z","timestamp":1232759770000},"page":"420-434","source":"Crossref","is-referenced-by-count":101,"title":["Carbapenems and Monobactams: Imipenem, Meropenem, and Aztreonam"],"prefix":"10.4065","volume":"74","author":[{"given":"Walter C.","family":"Hellinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson S.","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/74.4.420_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/AAC.22.1.62","article-title":"Metabolism of thienamycin and related carbapenem antibiotics by trie renal dipepti-dase, dehydropeptidase I","volume":"22","author":"Krapp","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib2","first-page":"3","article-title":"Carbapenems. a new class of beta-lactam antibiotics: discovery and development of imipenem\/cilastatin","volume":"78","author":"Birnbaum","year":"1985","journal-title":"AmJMed"},{"key":"10.4065\/74.4.420_bib3","first-page":"301","article-title":"Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of AJ-formimidoyl thienamycin dehydropeptidase inhibitors","volume":"23","author":"Norrby","year":"1983","journal-title":"Antimicrob Agents Chemolher"},{"key":"10.4065\/74.4.420_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1128\/AAC.27.1.84","article-title":"Diffusion of (1-lactam antibiotics through the porin channels of Escherichia coli K-12","volume":"27","author":"Yoshimura","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib5","first-page":"892","article-title":"Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms","volume":"10","author":"Quinn","year":"1988","journal-title":"flev Mecf D;s"},{"key":"10.4065\/74.4.420_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0025-7125(16)30759-3","article-title":"Imipenem: a new carbapenem antibiotic","volume":"72","author":"Ltpman","year":"1988","journal-title":"JVfed Clin North Am"},{"issue":"Suppl D","key":"10.4065\/74.4.420_bib7","doi-asserted-by":"crossref","first-page":"l","DOI":"10.1093\/jac\/12.suppl_D.1","article-title":"Thienamycin: development of imipenem-cifastatin","volume":"12","author":"Kahan","year":"1983","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib8","first-page":"22","article-title":"Review of the in vitro spectrum of activity of imipenem","volume":"78","author":"Jones","year":"1985","journal-title":"AmJMed"},{"key":"10.4065\/74.4.420_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/25.1.57","article-title":"Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate","volume":"25","author":"Bellldo","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/AAC.22.4.564","article-title":"Purification and properties of inducible penicillin B-lactamase isolated from Pseudomonas maltophilia","volume":"22","author":"Salno","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1128\/AAC.30.5.645","article-title":"\u03b2-Lactamase mediated imipenem resistance in Sacteroides fragilis","volume":"30","author":"Cuchural","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/17.1.45","article-title":"\u03b2-Lactamases with high activity against imipenem and 5ch 34343 from Aeromonas hydrophila","volume":"17","author":"Shannon","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/infdis\/155.4.775","article-title":"\u03b2-Lactamase lability and inducer power cf newer \u03b2-lactam antibiotics in relation to their activity against 6-lactamase-inducibility mutants of Pseudomonas aeruginosa","volume":"155","author":"Llvermore","year":"1987","journal-title":"J Infect Dis"},{"key":"10.4065\/74.4.420_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1128\/AAC.28.1.41","article-title":"Imipenem-induced resistance to antipseudomonal \u03b2-lactams in Pseudomonas aeruginosa","volume":"28","author":"Tausk","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.7326\/0003-4819-103-4-552","article-title":"Imipenem: first of a new class of beta-lactam antibiotics","volume":"103","author":"Barza","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.4065\/74.4.420_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000410477","article-title":"An evaluation of antipseudomonal antimicrobic agents","volume":"36","author":"Gilbert","year":"1985","journal-title":"Antibiot Chemother"},{"issue":"Suppl 5","key":"10.4065\/74.4.420_bib17","doi-asserted-by":"crossref","first-page":"S917","DOI":"10.1093\/clinids\/11.Supplement_5.S917","article-title":"Laboratory survey of fluoroquinolone activity","volume":"11","author":"Bellldo","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.4065\/74.4.420_bib18","series-title":"Antibiotics in Laboratory Medicine","first-page":"159","article-title":"Antimicrobial susceptibility testing of anaerobes","author":"Rosenblatt","year":"1986"},{"key":"10.4065\/74.4.420_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0732-8893(93)90110-S","article-title":"Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria","volume":"16","author":"Murray","year":"1993","journal-title":"Diagn Microbio) Infect Dis"},{"issue":"Suppl 31","key":"10.4065\/74.4.420_bib20","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.1093\/clinids\/7.Supplement_3.S389","article-title":"Antibacterial activity of imipenem: the first thienamycin antibiotic","volume":"7","author":"Kropp","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.4065\/74.4.420_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2165\/00003495-199244030-00008","article-title":"imipenem\/cilastatin: a reappraisal of its antibacterial activity, pharmacakinetic properties and therapeutic efficacy [published erratum appears in Drugs 1992:44:1012]","volume":"44","author":"Buckley","year":"1992","journal-title":"Drugs"},{"key":"10.4065\/74.4.420_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003495-199651010-00008","article-title":"Imipenem\/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections","volume":"51","author":"Balfour","year":"1996","journal-title":"Drugs"},{"key":"10.4065\/74.4.420_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00003495-199550010-00007","article-title":"Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy","volume":"50","author":"Wiseman","year":"1995","journal-title":"Drugs"},{"key":"10.4065\/74.4.420_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/646417","article-title":"Resistance to imipenem among selected gram negative bacilli in the United States","volume":"13","author":"Gaynes","year":"1992","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.4065\/74.4.420_bib25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0732-8893(94)90033-7","article-title":"Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: real or perceived?","volume":"19","author":"Jones","year":"1994","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.4065\/74.4.420_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0924-8579(95)00007-U","article-title":"Cefotaxirne resistant gram-negative bacilli in a university hospital: occurrence, identity, source and sensitivity patterns","volume":"5","author":"Hamilton-Miller","year":"1995","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl B","key":"10.4065\/74.4.420_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/32.suppl_B.81","article-title":"Canadian survey of antimicrobial resistance in Hleb-siella spp. anfl Enterobacter spp","volume":"32","author":"Toy","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib28","first-page":"286","article-title":"In vitro activity of biapenem versus ceftazidime-resistant strains of Klebsiella pneumoniae and Escherichia coli [abstract]","volume":"33","author":"Cherubin","year":"1993","journal-title":"Program Abstr Intersci Conf Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0732-8893(94)90048-5","article-title":"Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime: a multilaboratory national and international clinical isolate study","volume":"19","author":"Jones","year":"1994","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.4065\/74.4.420_bib30","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/clinids\/23.4.779","article-title":"Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program","volume":"23","author":"Itokazu","year":"1996","journal-title":"Clin infect Dis"},{"key":"10.4065\/74.4.420_bib31","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.31.10.1553","article-title":"Entry of roxithromycin (RU 965). imipenem. cerotaxime, trimethoprim. and metronidazole into human polymorphonucfear leukocytes","volume":"31","author":"Hand","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib32","first-page":"10821083","article-title":"Synergism between N-formimidoyl thienamycin and gentamicin or tobramycin against enterococci","volume":"22","author":"Watanakunakom","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.19.5.789","article-title":"Susceptibility of enterococci and Listeria monocytogenes to N-formimidoyl thienamycin alone and in combination with an aminoglycoside","volume":"19","author":"Ellopoulos","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib34","first-page":"725","article-title":"In vitro activity of w-formimidoyl thienamycin agamst Pseudomonas and staphylococci associated with endocarditis","volume":"1","author":"Kallick","year":"1982","journal-title":"Curr Chemother Immunother"},{"key":"10.4065\/74.4.420_bib35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/clinids\/5.2.314","article-title":"Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa","volume":"5","author":"Reyes","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.4065\/74.4.420_bib36","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1128\/AAC.23.4.626","article-title":"Comparative in vitro susceptibilities of anaerobic bacteria to eefmenoxime, cefotetan, and N-formimidoyl thienamycin","volume":"23","author":"Owen","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/AAC.34.1.117","article-title":"Imipenem resistance in Bacteroides distasonis mediated by a novel \u03b2-lactamase","volume":"34","author":"Hurlbut","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib38","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1128\/AAC.31.9.1434","article-title":"In vitro activity of cefmetazole, cefotetan, amoxicillin-clavulanic acid, and other antimicrobial agents against anaerobic bacteria from endometrial cultures of women with pelvic infections","volume":"31","author":"Ohm-Smith","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/AAC.32.5.717","article-title":"Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation","volume":"32","author":"Cuchural","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0732-8893(94)90026-4","article-title":"A five-year multicenter study of the suscepti bility of the Bacteroides fragilis group Isolates to cephalosporins. cephamins, penicillins, clindamycin, and metronidazole in the United States","volume":"18","author":"Aldridge","year":"1994","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 1","key":"10.4065\/74.4.420_bib41","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1093\/clinids\/23.Supplement_1.S54","article-title":"Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994","volume":"23","author":"Snydman","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.4065\/74.4.420_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/jac\/29.2.169","article-title":"In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp","volume":"29","author":"Yazawa","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib43","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1128\/AAC.37.4.882","article-title":"In vitro antimicrobial susceptibilities of Nocardia species","volume":"37","author":"Hhardori","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/1120009X.1994.11741125","article-title":"Activity of antimicrobial drugs evaluated by agar dilution and radiometric methods against strains of Nocardia ast\u00e9ro\u00efdes isolated in Italy from immunocompromised patients","volume":"6","author":"Scopettl","year":"1994","journal-title":"J Chemother"},{"key":"10.4065\/74.4.420_bib45","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.22.6.1079","article-title":"In vitro susceptibility of Mycobacterium fortuitum to AMormimidoyl thienamycin and several cephamycins","volume":"22","author":"Cynamon","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib46","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1128\/AAC.28.6.807","article-title":"Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycofjacferium chelonae [published erratum appears in Antimicrob Agents Chemother 1986:29:720]","volume":"28","author":"Swenson","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib47","first-page":"188","article-title":"Clinical features and treatment of infection due to Mycobacterium fortuitum\/chelonae complex","volume":"13","author":"McFarland","year":"1993","journal-title":"Curr Clin Top Infect Dis"},{"key":"10.4065\/74.4.420_bib48","first-page":"285","article-title":"Imipenem [Imi] + Amikacin [Ak] in combination chemotherapy of multiple-drug resistant [MDR] tuberculosis [TB] [abstract]","volume":"36","author":"Chambers","year":"1996","journal-title":"Program Abstr Intersci Conf Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0891-5520(20)30292-0","article-title":"Imipenem and aztreonam","volume":"3","author":"Sobol","year":"1989","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl E","key":"10.4065\/74.4.420_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/18.Supplement_E.79","article-title":"An overview of the pharmacology of imipenem\/cilastatin","volume":"18","author":"Drusano","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1128\/AAC.29.2.188","article-title":"Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections","volume":"29","author":"MacGregor","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl E","key":"10.4065\/74.4.420_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/18.Supplement_E.93","article-title":"The pharmacokinetics and tissue penetration of imipenem","volume":"18","author":"Wise","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jac\/20.4.618","article-title":"Imipenem penetration into bronchial secretions [letter)","volume":"20","author":"Muller-Serleys","year":"1987","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib54","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/jac\/20.5.725","article-title":"Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy","volume":"20","author":"Benonl","year":"1987","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib55","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0002-9394(87)90180-2","article-title":"Penetration of imipenem into human aqueous and vitreous humor","volume":"104","author":"Axelrod","year":"1987","journal-title":"Am J Ophthalmol"},{"key":"10.4065\/74.4.420_bib56","first-page":"601","article-title":"Imipenem penetration into the cerebrosoinal fluid of patients with meningitis [abstract]","volume":"24","author":"Modal","year":"1984","journal-title":"Program Abstr Intersci Conf Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib57","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.26.5.707","article-title":"Disposition of radiolabeled imipenem and cilastatin in normal human volunteers","volume":"26","author":"Norrby","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02017379","article-title":"Impact of imipenem\/cilastatin therapy on faecal flora","volume":"3","author":"Nord","year":"1984","journal-title":"Eur J Clin Microbiol"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9343(85)90100-7","article-title":"Impact of imipenem\/cilastatin therapy on normal fecal flora","volume":"78","author":"Wexler","year":"1985","journal-title":"Am J Med"},{"key":"10.4065\/74.4.420_bib60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2165\/00003088-199426060-00004","article-title":"Clinical pharmacokinetics during continuous haemofiltration","volume":"26","author":"Bressolle","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"10.4065\/74.4.420_bib61","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0002-9343(88)90071-X","article-title":"Factors predisposing to seizures m seriously ill infected patients receiving antibiotics: experience with imipenem\/cilastatin","volume":"84","author":"Calandra","year":"1988","journal-title":"Am J Med"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0002-9343(85)90102-0","article-title":"Imipenem\/cilastatin: phar-macokmetic profile in renal insufficiency","volume":"78","author":"Gibson","year":"1985","journal-title":"Am J Med"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0002-9343(85)90113-5","article-title":"Efficacy of imipenem\/cilastatin in endocarditis","volume":"78","author":"Dickinson","year":"1985","journal-title":"Am J Med"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib64","first-page":"9599","article-title":"Imipenem\/cilastatin therapy of bacteremia","volume":"78","author":"Eron","year":"1985","journal-title":"Am J Med"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib65","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0002-9343(85)90110-X","article-title":"Pneumonia treated with imipenem\/cilastatin","volume":"78","author":"Salata","year":"1985","journal-title":"Am J Med"},{"issue":"Suppl 3","key":"10.4065\/74.4.420_bib66","doi-asserted-by":"crossref","first-page":"S513","DOI":"10.1093\/clinids\/7.Supplement_3.S513","article-title":"Therapy for lower respiratory tract infections with imipenem\/ciiastatin: a review of worldwide experience","volume":"7","author":"Acar","year":"1985","journal-title":"Rev Infect Dis"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib67","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/0002-9343(85)90111-1","article-title":"Treatment of skin and soft tissue infections with imipenem\/cilastatin","volume":"78","author":"Fass","year":"1985","journal-title":"Am J Med"},{"key":"10.4065\/74.4.420_bib68","first-page":"15","article-title":"Imipenem\/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics","volume":"52","author":"Calandra","year":"1987","journal-title":"Scand J infect Dis Suppl"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib69","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0002-9343(85)90107-X","article-title":"Safety and efficacy of imipenem\/cilastatin in treatment of complicated urinary tract infections","volume":"78","author":"Cox","year":"1985","journal-title":"Am J Med"},{"issue":"Suppl 3","key":"10.4065\/74.4.420_bib70","doi-asserted-by":"crossref","first-page":"S518","DOI":"10.1093\/clinids\/7.Supplement_3.S518","article-title":"Imipenem\/cilastatin in the treatment of ntraabdominal infections: a review of worldwide experience","volume":"7","author":"Kager","year":"1985","journal-title":"Rev Infect Dis"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0002-9343(85)90105-6","article-title":"Imipenem\/cilastatin in the treatment of obstetric and gynecologic infections","volume":"78","author":"Berkeley","year":"1985","journal-title":"Am J Med"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib72","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/0002-9343(85)90109-3","article-title":"Imipenem\/cilastatin in the treatment of osteomyelitis","volume":"78","author":"MacGregor","year":"1985","journal-title":"Am J Med"},{"key":"10.4065\/74.4.420_bib73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/1097-0142(19870715)60:2<255::AID-CNCR2820600224>3.0.CO;2-L","article-title":"Imipenem\/cilastatin therapy of infections m cancer patients","volume":"60","author":"Bodey","year":"1987","journal-title":"Cancer"},{"issue":"Suppl D","key":"10.4065\/74.4.420_bib74","doi-asserted-by":"crossref","first-page":"13J139","DOI":"10.1093\/jac\/12.suppl_D.133","article-title":"Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin","volume":"12","author":"Marier","year":"1983","journal-title":"J Antimicrob Chemother"},{"issue":"5uppl D","key":"10.4065\/74.4.420_bib76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jac\/12.suppl_D.141","article-title":"Comparative study of imipenem in severe infections","volume":"12","author":"Baumgartner","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib75","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.24.6.841","article-title":"Imipenem versus moxalactam in the treatment of serious infections","volume":"24","author":"Eron","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib77","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/BF02017380","article-title":"A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem\/cilaslatin and moxalactam","volume":"3","author":"Calandra","year":"1984","journal-title":"Eur J Clin Microbio)"},{"key":"10.4065\/74.4.420_bib78","first-page":"204","article-title":"Randomized. comparative trial of imipenem\/cilastatin and moxalactam in the treatment of serious obstetric and gynecologic infections","volume":"162","author":"Berkeley","year":"1986","journal-title":"Surg Gynecol Obstet"},{"key":"10.4065\/74.4.420_bib79","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/22953337.1987.11719261","article-title":"Randomized comparison of imipenem\/cilastatin and ceftazidime in the empiric therapy of severe abdominal infections: a multicenter study","volume":"42","author":"Broze","year":"1987","journal-title":"Acta Clin Belg"},{"key":"10.4065\/74.4.420_bib80","doi-asserted-by":"crossref","first-page":"14911496","DOI":"10.1128\/AAC.31.10.1491","article-title":"Prospective randomized controlled study of ciprofioxacin versus imipenem\/cilaslatin in severe clinical infections","volume":"31","author":"Lode","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib81","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/00365548709117202","article-title":"Imipenem\/cilastatin as monotherapy in severe infections: comparison with cefotaxime in combination with metronidazole and cloxacillin; report from a Norwegian study group","volume":"19","year":"1987","journal-title":"Scand J infect Dis"},{"key":"10.4065\/74.4.420_bib82","first-page":"86","article-title":"Imipenem\/cilastatin versus gentamicin\/clindamycin for treatment of serious bacterial infections; report from a Scandinavian study group","volume":"1","year":"1984","journal-title":"Lancet"},{"key":"10.4065\/74.4.420_bib83","first-page":"43","article-title":"Imipenem therapy for perforated and gangrenous appendicitis","volume":"162","author":"Hesettlne","year":"1986","journal-title":"Surg Gynecol Obstet"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0002-9343(85)90106-8","article-title":"Randomized trial of imipenem\/cilastatin versus gentamicin and clindamycin in mixed flora infections","volume":"78","author":"Solomkln","year":"1985","journal-title":"Am J Med"},{"key":"10.4065\/74.4.420_bib85","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archsurg.1988.01400270056008","article-title":"Pre-spective study comparing imipenem-cilastatin with clindamycin and gentamicin for the treatment of serious surgical infections","volume":"123","author":"Hacktord","year":"1988","journal-title":"Arch Surg"},{"issue":"Suppl 3","key":"10.4065\/74.4.420_bib86","doi-asserted-by":"crossref","first-page":"S463","DOI":"10.1093\/clinids\/7.Supplement_3.S463","article-title":"Imipenem\/cilastatin vs. gentamicin\/clindamycin for the treatment of moderate to severe infections in hospitalized patients","volume":"7","author":"Guerra","year":"1985","journal-title":"Rev Infect Dis"},{"issue":"Suppl 3","key":"10.4065\/74.4.420_bib87","first-page":"S452","article-title":"Prospective randomized comparison of imipenem\/cilaslatin and cefotaxime for treatment of lung, soft tissue, and renal infections","volume":"7","author":"Dlaz-Mltoma","year":"1985","journal-title":"Rev Infect Dis"},{"issue":"Suppl 3","key":"10.4065\/74.4.420_bib88","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1093\/clinids\/7.Supplement_3.S458","article-title":"Comparative clinical evaluation of imipenem\/cilastatin vs. cefotaxime in treatment of severe bacterial infections","volume":"7","author":"Stamboullan","year":"1985","journal-title":"Rev infect Dis"},{"key":"10.4065\/74.4.420_bib89","first-page":"109","article-title":"Imipenem and aztreonam: current role in antimicrobial therapy","volume":"10","author":"Rice","year":"1989","journal-title":"Curr Clin Top Infect Dis"},{"key":"10.4065\/74.4.420_bib90","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1155\/1993\/567478","article-title":"A prospective, randomized trial of imipenem-cilastatin versus clindamycin\/tobramycin in the treatment of intra-abdominal and pelvic infection","volume":"4","author":"Mandel)","year":"1993","journal-title":"Can J Infect Dis"},{"key":"10.4065\/74.4.420_bib91","first-page":"415","article-title":"Imipenem versus tobramycin-antianaerobe antibiotic therapy in intra-abdominal infections","volume":"33","author":"Poenaru","year":"1990","journal-title":"Can J Surg"},{"key":"10.4065\/74.4.420_bib92","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/jac\/32.3.491","article-title":"Comparison of imipenem\/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections-","volume":"32","author":"de Groot","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib93","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00000658-199603000-00012","article-title":"Results of a randomized trial comparing sequential intravenous\/oral treatment with ciprofioxacin plus metronidazole to imipenem\/cilastatin for intra-abdominal infections","volume":"223","author":"Solomkln","year":"1996","journal-title":"Ann Surg"},{"key":"10.4065\/74.4.420_bib94","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1128\/AAC.36.12.2766","article-title":"Piperaciliin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections","volume":"36","author":"Brlsmar","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib95","first-page":"255","article-title":"Piperacillin\/tazobactam versus imipenem\/cilaslatin in the treatment of int\/a-abdominal infections","volume":"176","author":"Nlinlkoski","year":"1993","journal-title":"Surg Gynecol Obstet"},{"key":"10.4065\/74.4.420_bib96","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0011-393X(05)80515-6","article-title":"Pharmacokinetics and prophylactic efficacy of imipenem in abdominal surgery","volume":"52","author":"Esposito","year":"1992","journal-title":"Curr Trier Res Clin Exp"},{"key":"10.4065\/74.4.420_bib97","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00006454-199206000-00005","article-title":"Imipenem-cilastatin vs. tobramycin and metronidazole for appenuicitis-related infections","volume":"11","author":"Uharl","year":"1992","journal-title":"Peo\u00efatr infect Dis J"},{"key":"10.4065\/74.4.420_bib98","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0195-6701(90)90037-O","article-title":"A comparison between imipenem and metronidazole prophylaxis against sepsis following appendicectomy","volume":"15","author":"Burkltt","year":"1990","journal-title":"JHosp Infect"},{"key":"10.4065\/74.4.420_bib99","first-page":"1196","article-title":"Imipenem prophylaxis in elective colorectal surgery","volume":"80","author":"Karran","year":"1993","journal-title":"BrJSurg"},{"key":"10.4065\/74.4.420_bib100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/1120009X.1991.11739123","article-title":"Single dose imipenem-cilastatin compared with three doses of cefuroxime and metronidazole as prophylaxis in elective colorectal surgery: a prospective randomized study","volume":"3","author":"Pacelll","year":"1991","journal-title":"J Chemother"},{"key":"10.4065\/74.4.420_bib101","first-page":"480","article-title":"A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem","volume":"176","author":"Pederzoli","year":"1993","journal-title":"Surg Gynecol Obstet"},{"key":"10.4065\/74.4.420_bib102","first-page":"607","article-title":"Prospective, randomized, controlled study of imipenem-cilastatin versus cefotaxime-amikacin in the treatment of lower respiratory tract infection and septicemia at intensive care units","volume":"19","author":"Mouton","year":"1990","journal-title":"Presse Med"},{"key":"10.4065\/74.4.420_bib103","first-page":"11311144","article-title":"Imipenem\/cilastatin sodium atone or combined with amikacin sulfate in respiratory infections","volume":"47","author":"Takamoto","year":"1994","journal-title":"Jon J Antibiot"},{"key":"10.4065\/74.4.420_bib104","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/jac\/31.6.927","article-title":"Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem\/cilastatin","volume":"31","author":"Norrby","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib105","doi-asserted-by":"crossref","first-page":"547557","DOI":"10.1128\/AAC.38.3.547","article-title":"Treatment of severe pneumonia in hospitalized patients: results of a muiticenter, randomized, double-blind trial comparing intravenous ciprofioxacin with imipenem-cilastatin","volume":"38","author":"Fink","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib106","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1128\/AAC.34.7.1336","article-title":"Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients","volume":"34","author":"Liang","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib107","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.1995.13.1.165","article-title":"Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem","volume":"13","author":"Freifeld","year":"1995","journal-title":"J CJrn Oncol"},{"key":"10.4065\/74.4.420_bib108","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/jac\/30.6.843","article-title":"A comparative study of imipenem versus pipefacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies [published erratum appears in J Antimicrob Chemother 1993:31:621)","volume":"30","author":"Leyland","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib109","first-page":"797","article-title":"Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vaneomycin versus ticarcillin-amikacin-vancomycin","volume":"40","author":"Bosseray","year":"1992","journal-title":"Pathol Bio) (Paris)"},{"issue":"Suppl lA","key":"10.4065\/74.4.420_bib110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0002-9343(88)90170-2","article-title":"Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients","volume":"85","author":"Mortimer","year":"1988","journal-title":"Am J Med"},{"key":"10.4065\/74.4.420_bib111","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7326\/0003-4819-115-11-849","article-title":"Betaiactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone","volume":"115","author":"Winston","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.4065\/74.4.420_bib112","first-page":"486","article-title":"Efficacy and tolerabitity of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenie cancer patients","volume":"15","author":"Miller","year":"1993","journal-title":"Clin Ther"},{"key":"10.4065\/74.4.420_bib113","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archinte.1992.00400140037010","article-title":"A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenie patients","volume":"152","author":"Rolston","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.4065\/74.4.420_bib114","first-page":"65","article-title":"Imipenem\/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenie patients: a prospective, randomized multi-clinic study","volume":"52","author":"Norrby","year":"1987","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.4065\/74.4.420_bib115","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00000421-199410000-00009","article-title":"A randomized prospective study of imipenem-cilaslatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenie patients","volume":"17","author":"Kojlma","year":"1994","journal-title":"Am JChn Oncol"},{"key":"10.4065\/74.4.420_bib116","first-page":"829","article-title":"Clinical efficacy of imipenem\/cilastatin sodium and amikacin combination therapy on severe infections in patients with hematologrcal disorders","volume":"30","author":"Wake","year":"1993","journal-title":"Shinryoto Shinyaku"},{"key":"10.4065\/74.4.420_bib117","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/clinids\/18.5.683","article-title":"Use or ampicillin\/sulbactam versus imipenem\/cilastatin in the treatment of limb-threatening foot infections in diabetic patients [published erratum appears in Clin Wect Dis 1994:19:820]","volume":"18","author":"Grayson","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.4065\/74.4.420_bib118","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF01780852","article-title":"Nocardial cerebral abscess cured with imipenem\/amikacin and enucleation","volume":"12","author":"Krone","year":"1989","journal-title":"Neurosurg Rev"},{"key":"10.4065\/74.4.420_bib119","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF01710686","article-title":"Successful treatment of brain abscess caused by Nocardia in an immunocompromised patient after failure of cc-trimoxazole","volume":"20","author":"Overkamp","year":"1992","journal-title":"Infection"},{"key":"10.4065\/74.4.420_bib120","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1378\/chest.103.3.951","article-title":"Use of imipenem in the treatment of pulmonary nocardiosis","volume":"103","author":"Lo","year":"1993","journal-title":"Chest"},{"key":"10.4065\/74.4.420_bib121","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0041-3879(90)90009-W","article-title":"Oftoxacin and imipenem in the treatment of Mycobacterium fortuitum and Mycobacterium chetonae lung infections","volume":"71","author":"Yew","year":"1990","journal-title":"Tubercle"},{"key":"10.4065\/74.4.420_bib122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/646416","article-title":"Resistance of Pseudomonas aeruginosa to imipenem [editorial]","volume":"13","author":"Neu","year":"1992","journal-title":"infect Control Hosp Epidemiol"},{"key":"10.4065\/74.4.420_bib123","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1128\/AAC.38.6.1309","article-title":"Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients","volume":"38","author":"Cometta","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 6A","key":"10.4065\/74.4.420_bib124","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0002-9343(85)90104-4","article-title":"Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem\/cilastatin","volume":"78","author":"Calandra","year":"1985","journal-title":"Am J Med"},{"key":"10.4065\/74.4.420_bib125","first-page":"305","article-title":"Adverse effects of monobactams and carba-penems","volume":"12","author":"Ah\/an","year":"1995","journal-title":"DrugSaf"},{"key":"10.4065\/74.4.420_bib126","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00007611-199104000-00013","article-title":"Seizures in patients simultaneously receiving the Dphylline and imipenem or ciprofloxacin or metronidazole","volume":"84","author":"Semel","year":"1991","journal-title":"South MedJ"},{"key":"10.4065\/74.4.420_bib127","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/106002809302700418","article-title":"Prospective surveillance of imipenem\/cilastatin use and associated seizures using a hospital information system","volume":"27","author":"Pestotnik","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.4065\/74.4.420_bib128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00006454-199102000-00009","article-title":"Imipenem\/cilastatin treatment of bacterial meningitis in children","volume":"10","author":"Wong","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"10.4065\/74.4.420_bib129","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7326\/0003-4819-107-2-204","article-title":"Immediate hypersensitiv-ity reactions to beta-laclam antibiotics","volume":"107","author":"Saxon","year":"1987","journal-title":"Ann intern Med"},{"key":"10.4065\/74.4.420_bib130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/30.2.129","article-title":"Inactivation of new carbapenem antibiotics by dehydropeptidase I from porcine and human renal cortex","volume":"30","author":"Hlklda","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib131","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.36.7.1577","article-title":"Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I","volume":"36","author":"Fukasawa","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib132","first-page":"5","article-title":"Laboratory data which differentiate meropenem and imipenem","volume":"96","author":"Edwards","year":"1995","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.4065\/74.4.420_bib133","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/AAC.39.1.232","article-title":"Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats","volume":"39","author":"De Samt","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib134","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.7164\/antibiotics.45.1983","article-title":"Structure-activity relationships of carbapenem and penem compounds for the convulsive property [letter]","volume":"45","author":"Sunagawa","year":"1992","journal-title":"J Antibiot (Tokyo)"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib135","doi-asserted-by":"crossref","first-page":"l","DOI":"10.1093\/jac\/36.suppl_A.1","article-title":"Meropenem: a microbiological overview","volume":"36","author":"Edwards","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib136","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/BF01963782","article-title":"In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338","volume":"8","author":"Sumrta","year":"1989","journal-title":"EurJChn Microbiol Infect Dis"},{"key":"10.4065\/74.4.420_bib137","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0962-8479(92)90145-A","article-title":"In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule","volume":"73","author":"Watt","year":"1992","journal-title":"Tuber Lung Dis"},{"issue":"Suppl 2J","key":"10.4065\/74.4.420_bib138","first-page":"S266","article-title":"The pharmacology of meropenem, a new carbapenem antibiotic","volume":"24","author":"Cralg","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.4065\/74.4.420_bib139","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/clinids\/21.3.544","article-title":"Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial","volume":"21","author":"Condon","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.4065\/74.4.420_bib140","first-page":"403407","article-title":"Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis","volume":"182","author":"Beme","year":"1996","journal-title":"J Am Coll Surg"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib141","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/36.suppl_A.179","article-title":"Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections","volume":"36","author":"Huizinga","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib142","first-page":"473479","article-title":"Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections [published erratum appears in Infection 1997;25:316]","volume":"24","author":"Kentpl","year":"1996","journal-title":"Infection"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib143","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/36.suppl_A.145","article-title":"Empirical monotherapy with meropenem in serious bacterial infections","volume":"36","author":"Mouton","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib144","first-page":"16631670","article-title":"Empiric treatment of hospital acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study [published erratum appears in Crit Care Med 1997;25:2067]","volume":"25","author":"Sieger","year":"1997","journal-title":"Crit Care Med"},{"issue":"Suppl 2","key":"10.4065\/74.4.420_bib145","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1093\/clinids\/24.Supplement_2.S222","article-title":"A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women","volume":"24","author":"Hemsell","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib146","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/jac\/36.suppl_A.157","article-title":"Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin","volume":"36","author":"Solberg","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib147","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/jac\/36.1.185","article-title":"Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenie patients","volume":"36","author":"Meropenem Study Group of Leuven, London and Nijmegen","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib148","first-page":"687","article-title":"Therapeutic effects ot meropenem against severe infections in patients with hematopaietic disorders","volume":"45","author":"Suglyama","year":"1992","journal-title":"Jpn J Antibiot"},{"key":"10.4065\/74.4.420_bib149","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.40.5.1108","article-title":"Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer","volume":"40","author":"Cometta","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/36.suppl_A.85","article-title":"A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults","volume":"36","author":"Schmutzhard","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib151","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1128\/AAC.39.5.1140","article-title":"Ran domized comparison of meropenem with cefotaxime for treatment of bacterial meningitis","volume":"39","author":"Klugman","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib152","series-title":"Abstracts of tfte 95th General Meeting of the American Society for Microbiology","article-title":"A multicenter study of meropenem vs. cefotaxime in the therapy of p\u00e9diatrie meningitis [abstract]","author":"Bradley","year":"1995"},{"issue":"Suppl 2","key":"10.4065\/74.4.420_bib153","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1093\/clinids\/24.Supplement_2.S213","article-title":"The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in Ihe 1990s","volume":"24","author":"Bradley","year":"1997","journal-title":"Clin Infect Ois"},{"key":"10.4065\/74.4.420_bib154","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0140-6736(92)90714-E","article-title":"High-dose meropenem in meningitis due to Pseudomonas aeruginosa [letter]","volume":"339","author":"Donnelly","year":"1992","journal-title":"Lancet"},{"key":"10.4065\/74.4.420_bib155","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/jac\/32.6.922","article-title":"Meropenem treatment or post traumatic meningitis due to Pseudomonas aeruginosa [letter]","volume":"32","author":"ChmeNk","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib156","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/36.suppl_A.135","article-title":"Clinical evaluation of meropenem versus ceftazidime for the treat ment of Pseudomonas spp. infections in cystic librosis patients","volume":"361","author":"Byrne","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib157","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jac\/35.1.139","article-title":"Meropenem versus imipenem\/cilastatin in the treatment of intra-abdominal infections","volume":"35","author":"Srlsmar","year":"1995","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib158","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/36.suppl_A.191","article-title":"Meropenem versus imipenem\/cilastatin in intra-abdominal infections requiring surgery","volume":"36","author":"Geroulanos","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib159","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01967440","article-title":"Meropenem versus imipenem\/cilastatin in the treatment of intraabdommal infections requiring surgery","volume":"12","author":"Kanellakopoulou","year":"1993","journal-title":"Eut J Clin Microbiol Infect Dis"},{"key":"10.4065\/74.4.420_bib160","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/38.3.523","article-title":"Intravenous meropenem versus imipenem\/cilastatin in the treatment of serious bacterial infections in hospitalized patients","volume":"38","author":"Colardyn","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib161","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/36.suppl_A.121","article-title":"Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients-a comparison of meropenem and imipenem\/cilastatin","volume":"36","author":"Hamacher","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib162","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0011-393X(05)80703-9","article-title":"Meropenem versus imipenem: relationship between microbiological parameters and clinical outcome in lower respiratory tract infections","volume":"54","author":"Rlzzato","year":"1993","journal-title":"Curr Wer Res Clin Exp"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib163","first-page":"10ail9","article-title":"Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts","volume":"36","author":"Romanelli","year":"1995","journal-title":"JAMA Chemother"},{"key":"10.4065\/74.4.420_bib164","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/clinids\/21.1.86","article-title":"A multicenter comparative study of meropenem and imipenem\/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients","volume":"21","author":"Cox","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.4065\/74.4.420_bib165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00007611-199504000-00003","article-title":"Meropenem versus imipenem\/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections (published erratum appears in South MedJ 1995;88:634]","volume":"88","author":"Nichols","year":"1995","journal-title":"South Med J"},{"key":"10.4065\/74.4.420_bib166","doi-asserted-by":"crossref","first-page":"480484","DOI":"10.1007\/BF01713054","article-title":"Empirical monotherapy with meropenem versus imipenem\/cilastatin for febrile episodes in neutropenic patients","volume":"24","author":"Shah","year":"1996","journal-title":"Infection"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib167","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jac\/24.suppl_A.307","article-title":"Meropenem: evidence of lack of proconvulsive tendency in mice","volume":"24","author":"Patel","year":"1989","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"10.4065\/74.4.420_bib168","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/36.suppl_A.207","article-title":"Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem","volume":"36","author":"Norrby","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib169","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/BF01963943","article-title":"Effect of meropenem on the intestinal microflora","volume":"10","author":"Bergan","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 4","key":"10.4065\/74.4.420_bib170","doi-asserted-by":"crossref","first-page":"S579","DOI":"10.1093\/clinids\/7.Supplement_4.S579","article-title":"Discovery and development of the monobactams","volume":"7","author":"Sykes","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.4065\/74.4.420_bib171","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1128\/AAC.30.6.906","article-title":"Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coll by some \u03b2-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam)","volume":"30","author":"Gutmann","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib172","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/14.4.313","article-title":"Structure activity relationships among the monobactams","volume":"14","author":"Bonner","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib173","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/AAC.21.1.85","article-title":"Azthreonam (SQ 26.776), a synthetic monobactam specifically active against aerobic gram-negative bacteria","volume":"21","author":"Sykes","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib174","series-title":"New fj-Lacram Antibiotics: A Review From Chemistry to Clinical Efficacy of the New Cephalosporins","first-page":"47","article-title":"Interaction of new \u03b2-lactams with \u03b2-lactamases and pMactamasfrproducing gram negative rods","author":"Bush","year":"1982"},{"key":"10.4065\/74.4.420_bib175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1128\/AAC.24.2.227","article-title":"In vitro activity and \u03b2-lactamase stability of a monobactam. SQ 26.917, compared with those of aztreonam and other agents","volume":"24","author":"Neu","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl E","key":"10.4065\/74.4.420_bib176","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/8.suppl_E.103","article-title":"SQ 26.776: in vitro antibacterial activity and susceptibility to [Hactamases","volume":"8","author":"Phillips","year":"1981","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl E","key":"10.4065\/74.4.420_bib177","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jac\/8.suppl_E.97","article-title":"In vitro activity of SQ 26,776 against multiply-resistant enlerobacteria-preliminary results","volume":"8","author":"Acar","year":"1981","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"10.4065\/74.4.420_bib178","doi-asserted-by":"crossref","first-page":"S594","DOI":"10.1093\/clinids\/7.Supplement_4.S594","article-title":"Aztreonam: antibacterial activity, \u03b2-laclamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests","volume":"7","author":"Barry","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.4065\/74.4.420_bib179","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1128\/AAC.21.2.294","article-title":"Comparative in vitro study of SQ26.776","volume":"21","author":"Falnstein","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl E","key":"10.4065\/74.4.420_bib180","first-page":"2037","article-title":"In-vitro activity of the monobactam, SQ 26,776, against gram-negative bacteria and its stability to their \u03b2-lactamases","volume":"8","author":"Uvermore","year":"1981","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib181","first-page":"955","article-title":"Activity of aztreonam and new beta-lactam antibiotics against penicillinase-producing Neisseria gonorrhoeae","volume":"34","author":"Strandberg","year":"1983","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.4065\/74.4.420_bib182","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1128\/AAC.25.2.212","article-title":"In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from p\u00e9diatrie patients","volume":"25","author":"Stutman","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib183","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1128\/AAC.25.2.283","article-title":"In vitro activity of aztreonam in combination with newer \u03b2-lactams and amikacin against multiply resistant gram-negative bacilli","volume":"25","author":"Buesing","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib184","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.25.2.279","article-title":"In vitro activities of aztreonam. piperacillin, and ticarcillin combined with amikacin against amikacin resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis","volume":"25","author":"Aronoff","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1128\/AAC.26.2.224","article-title":"Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens. and Pseudomonas aeruginosa","volume":"26","author":"Van Laethem","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib186","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1128\/AAC.24.1.18","article-title":"Pharmacology of aztreonam after intravenous infusion","volume":"24","author":"Scully","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib187","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/AAC.24.3.394","article-title":"Metabolism and pharmacokinetics of aztreonam in healthy subjects","volume":"24","author":"Swabb","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib188","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/AAC.25.3.358","article-title":"Biliary excretion of aztreonam in patients with biliary 1ract disease","volume":"25","author":"Martinez","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib189","doi-asserted-by":"crossref","first-page":"252261","DOI":"10.1128\/AAC.24.2.252","article-title":"Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction","volume":"24","author":"Mihindu","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib190","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ki.1984.174","article-title":"Effect of hemodiatysis and peritoneal dialysis on aztreonam pharmacokinetics","volume":"26","author":"Gerig","year":"1984","journal-title":"Kidney int"},{"key":"10.4065\/74.4.420_bib191","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/AAC.26.5.730","article-title":"Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed m\u00e9ninges","volume":"26","author":"Duma","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib192","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.29.2.281","article-title":"P\u00e9n\u00e9tration of aztreonam into cerebrospinal fluid of patients with bacterial meningitis","volume":"29","author":"Modal","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib193","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.26.2.245","article-title":"Evaluation of aztreonam in difficult-to-treat infections with prolonged posttreatment follow-up","volume":"26","author":"Glamarellou","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/74.4.420_bib194","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/infdis\/150.5.623","article-title":"Treatment of serious gram-negative infections with aztreonam","volume":"150","author":"Greenberg","year":"1984","journal-title":"J Infect Dis"},{"issue":"Suppl 2A","key":"10.4065\/74.4.420_bib195","first-page":"44","article-title":"Aztreonam in the treatment of urinary tract infection","volume":"78","author":"Childs","year":"1985","journal-title":"Am JMed"},{"issue":"Suppl 4","key":"10.4065\/74.4.420_bib196","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1093\/clinids\/7.Supplement_4.S767","article-title":"Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria","volume":"7","author":"Cox","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.4065\/74.4.420_bib197","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00006250-198605000-00010","article-title":"Treatment of acute pelvic inflammatory disease with aztreonam, a new rnoriocyclic \u03b2-1actam antibiotic, and clindamycin","volume":"67","author":"Dodsan","year":"1986","journal-title":"Obstet Cynecol"},{"issue":"Suppl 2A","key":"10.4065\/74.4.420_bib198","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(85)90204-9","article-title":"Aztreonam plus clindamycin as therapy for pelvic infections in women","volume":"78","author":"Pastorek","year":"1985","journal-title":"Am J Med"},{"key":"10.4065\/74.4.420_bib199","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/hep.1840060516","article-title":"Evaluation of aztreonam in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis","volume":"6","author":"Artza","year":"1986","journal-title":"Hepatology"},{"key":"10.4065\/74.4.420_bib200","doi-asserted-by":"crossref","first-page":"141147","DOI":"10.1093\/jac\/25.1.141","article-title":"Pharmacoki netics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPO peritonitis","volume":"25","author":"Brown","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/74.4.420_bib201","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00000658-198702000-00006","article-title":"Surgically treated gangrenous or perforated appendicitis: a comparison of aztreonam and clindamycin versus gentamicin and clindamycin","volume":"205","author":"Berne","year":"1987","journal-title":"Ann Surg"},{"issue":"Suppl 4","key":"10.4065\/74.4.420_bib202","first-page":"S724","article-title":"Aztreonam pi LIS clindamycin vs. tobramycin plus clindamycin for the treatment of intraabdominal infections","volume":"7","author":"Birolinl","year":"1985","journal-title":"Med infect Dis"},{"key":"10.4065\/74.4.420_bib203","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1386::AID-CNCR25>3.0.CO;2-X","article-title":"A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients","volume":"77","author":"Raad","year":"1996","journal-title":"Cancer"},{"key":"10.4065\/74.4.420_bib204","first-page":"225","article-title":"The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aerugmosa","volume":"23","author":"Walton","year":"1997","journal-title":"Bums"},{"issue":"Suppl 4","key":"10.4065\/74.4.420_bib205","doi-asserted-by":"crossref","first-page":"S783","DOI":"10.1093\/clinids\/7.Supplement_4.S783","article-title":"Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli","volume":"71","author":"Simons","year":"1985","journal-title":"Rev infect Dis"},{"key":"10.4065\/74.4.420_bib206","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-9343(85)90205-0","article-title":"Aztreonam in the treatment of serious orthopedic infections","volume":"78","author":"Pribyl","year":"1985","journal-title":"Am J Med"},{"key":"10.4065\/74.4.420_bib207","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/AAC.29.2.359","article-title":"Aztreonam treatment of gram-negative septicemia","volume":"29","author":"Pierard","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 4","key":"10.4065\/74.4.420_bib208","doi-asserted-by":"crossref","first-page":"S789","DOI":"10.1093\/clinids\/7.Supplement_4.S789","article-title":"Clinical experience with aztreonam in the treatment of gram-negative bacteremia","volume":"7","author":"Scully","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.4065\/74.4.420_bib209","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0002-9343(86)90258-5","article-title":"Aztreonam therapy in neutropenic patients with cancer","volume":"81","author":"Jones","year":"1986","journal-title":"Am J Med"},{"key":"10.4065\/74.4.420_bib210","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/AAC.27.2.246","article-title":"Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycm in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli","volume":"27","author":"Rodriguez","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2A","key":"10.4065\/74.4.420_bib211","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0002-9343(85)90201-3","article-title":"Treatment with aztreonam or tobramycin in critical care patients with nasocomial gram-negative pneumonia","volume":"78","author":"Schentag","year":"1985","journal-title":"Am J Med"},{"issue":"Suppl 4","key":"10.4065\/74.4.420_bib212","first-page":"S666","article-title":"Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli","volume":"7","author":"Molen","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.4065\/74.4.420_bib213","first-page":"279","article-title":"Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies","volume":"15","author":"Fish","year":"1995","journal-title":"Pfiarmacotfierapy"},{"key":"10.4065\/74.4.420_bib214","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000239466","article-title":"Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center","volume":"42","author":"Rolston","year":"1996","journal-title":"Chemotherapy"},{"issue":"Suppl 4","key":"10.4065\/74.4.420_bib215","doi-asserted-by":"crossref","first-page":"S648","DOI":"10.1093\/clinids\/7.Supplement_4.S648","article-title":"Safety profile of aztreonam in clinical trials","volume":"7","author":"Newman","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.4065\/74.4.420_bib216","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/0140-6736(90)92661-Z","article-title":"Immediate hypersensitivity to aztreonam [letter]","volume":"335","author":"Soto Alvarez","year":"1990","journal-title":"Lancet"},{"key":"10.4065\/74.4.420_bib217","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/bmj.302.6771.294-e","article-title":"Immediate hypersensitivity to aztreonam and imipenem [letter]","volume":"302","author":"Hantson","year":"1991","journal-title":"BMJ"},{"key":"10.4065\/74.4.420_bib218","series-title":"Azactam [package insert]","year":"1991"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611644108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611644108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T13:53:05Z","timestamp":1633009985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611644108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":218,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["S0025619611644108"],"URL":"https:\/\/doi.org\/10.4065\/74.4.420","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[1999,4]]}}}